0.91
-0.0185(-1.99%)
Currency In USD
Address
900 North Point Parkway
Alpharetta, GA 30005
United States of America
Phone
678 270 3631
Website
Sector
Healthcare
Industry
Biotechnology
Employees
30
First IPO Date
June 02, 2016
| Name | Title | Pay | Year Born |
| Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. | President, Chief Executive Officer & Director | 836,154 | 1952 |
| Mr. Charles A. Deignan | Chief Financial Officer | 568,676 | 1964 |
| Ms. Jenny R. Kobin | Head of Investor Relations | 0 | 1967 |
| Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D. | Chief Medical Officer | 0 | N/A |
| Mr. Rafael V. Andino | Senior Vice President of Engineering & Manufacturing | 0 | 1965 |
| Ms. Susan L. Coultas Ph.D. | Chief Clinical Officer | 0 | N/A |
| Mr. Rick McElheny | Senior Vice President of Corporate Development & Alliance Management | 0 | N/A |
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.